Novabay Pharmaceuticals Inc EBITDA margin
What is the EBITDA margin of Novabay Pharmaceuticals Inc?
The EBITDA margin of Novabay Pharmaceuticals Inc is -94.10%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with ebitda margin similar to Novabay Pharmaceuticals Inc
- Redhill Biopharma has EBITDA margin of -94.69%
- Turnium Technology Inc has EBITDA margin of -94.53%
- Clubhouse Media has EBITDA margin of -94.45%
- CAA Resources has EBITDA margin of -94.45%
- China Netcom Technology has EBITDA margin of -94.29%
- Blueprint Medicines Corp has EBITDA margin of -94.10%
- Novabay Pharmaceuticals Inc has EBITDA margin of -94.10%
- Valeo Pharma Inc has EBITDA margin of -94.00%
- Punjab Communications has EBITDA margin of -93.94%
- Immutep has EBITDA margin of -93.90%
- Blackbird plc has EBITDA margin of -93.74%
- DC Two has EBITDA margin of -93.62%
- Shanghai Junshi Biosciences Co has EBITDA margin of -93.51%